Lonza Group AG Key word Annual Results Lonza Delivers Solid 2023 Performance with 109% CER Sales Growth and 298% CORE EBITDA Margin 26Jan2024 0650 CETCEST Release of an ad hoc announcement pursuant t
Lonza Group AG Key word Personnel JeanMarc Huët to succeed Albert M Baehny as Chairman of Lonza 26Jan2024 0701 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issuer is solel
Lonza's chairman has ruled out plans to use its capacity to fill syringes and provide final production steps for new obesity drugs even as rivals scramble for a share of the booming weight-loss market. That marks a climb down from remarks at an investor event a month ago, when Albert Baehny said that Lonza would participate in the obesity therapy market thanks to its growing fill and finish capacity. The new obesity drugs, based on a class of peptides known as glucagon-like peptide-1 (GLP-1) receptor agonists, would not feature in Lonza's growth plans, despite the Swiss company producing a secondary ingredient for one such drug, Baehny said in an interview.
Lonza Group AG Key word Forecast Capital Markets Day 2023 New MidTerm Guidance 2024 – 2028 Supported by RampUp of Growth Projects 17Oct2023 0700 CETCEST Release of an ad hoc announcement pursuant to